Halozyme Therapeutics, Inc. (HALO)
| Market Cap | 7.60B +4.1% |
| Revenue (ttm) | 1.40B +37.6% |
| Net Income | 316.89M -28.6% |
| EPS | 2.56 -25.4% |
| Shares Out | 118.47M |
| PE Ratio | 25.05 |
| Forward PE | 7.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,650,409 |
| Open | 65.44 |
| Previous Close | 65.19 |
| Day's Range | 64.00 - 65.78 |
| 52-Week Range | 47.50 - 82.22 |
| Beta | 0.88 |
| Analysts | Buy |
| Price Target | 78.64 (+22.65%) |
| Earnings Date | May 11, 2026 |
About HALO
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini... [Read more]
Financial Performance
In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HALO stock is "Buy." The 12-month stock price target is $78.64, which is an increase of 22.65% from the latest price.
News
Halozyme announces global collaboration and license agreement with GSK
Halozyme Therapeutics (HALO) announced the company entered into a global collaboration and license agreement with GSK (GSK). Under the collaboration, GSK has licensed Halozyme’s ENHANZE drug delivery ...
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Marks first ENHANZE ® agreement to include ADC targets Collaboration also includes option for additional future targets First clinical trial projected to initiate in 2026 SAN DIEGO, May 7, 2026 /PRNew...
Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis
Halozyme (HALO) and Oruka Therapeutics (ORKA) announced that Halozyme’s wholly-owned subsidiary, Halozyme Hypercon, has entered into a global exclusive collaboration and license agreement with Oruka. ...
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Na...
Halozyme Therapeutics Transcript: AGM 2026
The meeting approved all proposals, including director elections and auditor ratification. Strong financial performance and pipeline expansion were highlighted, with new agreements and acquisitions positioning for future growth. Shareholder Q&A addressed capital allocation and ongoing litigation.
Halozyme to Report First Quarter 2026 Financial and Operating Results
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its first quarter 2026 financial and operating results on Monday, May ...
Halozyme names Darren Snellgrove as CFO
Halozyme Therapeutics (HALO) announced the appointment of Darren Snellgrove as CFO, effective June 8. Snellgrove will be responsible for leading Halozyme’s financial operations and strategy, including...
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of Darren Snellgrove as Chief Financial Officer, effe...
Halozyme price target raised to $95 from $90 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme (HALO) to $95 from $90 and keeps a Buy rating on the shares. A Q1 royalty reset is
Halozyme price target raised to $96 from $94 at Morgan Stanley
Morgan Stanley yesterday raised the firm’s price target on Halozyme (HALO) to $96 from $94 and keeps an Overweight rating on the shares. The firm adjusted the target as part
Halozyme enters global global collaboration and license agreement with Vertex
Halozyme (HALO) announced its wholly-owned subsidiary, Halozyme Hypercon, entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (VRTX). Under the collaboratio...
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
SAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a g...
Halozyme names David Ramsay as Interim CFO
Halozyme (HALO) announced that David Ramsay has been appointed Interim CFO, effective March 23. Ramsay will oversee all financial operations while the company continues its active search for a permane...
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer ...
Halozyme Therapeutics Transcript: The Citizens Life Sciences Conference 2026
Revenue is projected to grow 22%–30% in 2024, driven by royalties from key SubQ products and new launches. Pipeline expansion, strategic acquisitions, and new partnerships are expected to sustain growth into the 2030s and 2040s, with Hypercon projected to generate $1 billion in royalties by the mid-2030s.
Halozyme Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Recent acquisitions and technology advances are expanding the pipeline and enabling entry into small-volume, at-home subcutaneous drug delivery. Strong financial growth, disciplined M&A, and robust partner interest support a doubling of commercialized and development products by 2028.
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression ‑free survival and overall survival versus standard of care regimens SAN DIEGO, March 6, 2026 /PR...
Halozyme Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Recent acquisitions and new ENHANZE deals are driving expansion into subcutaneous drug delivery, with HyperCon assets poised for rapid growth and significant royalty potential. Patent extensions and minimal Medicare exposure support long-term revenue durability, while innovation in delivery formats accelerates adoption across major therapies.
Halozyme to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present a...
Halozyme price target raised to $94 from $78 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Halozyme (HALO) to $94 from $78 and keeps an Overweight rating on the shares after the company reported “strong” Q4 results. The
Halozyme price target raised to $90 from $75 at Benchmark
Benchmark raised the firm’s price target on Halozyme (HALO) to $90 from $75 and keeps a Buy rating on the shares following what the firm describes as “strong quarterly results
Halozyme price target raised to $75 from $65 at Wells Fargo
Wells Fargo raised the firm’s price target on Halozyme (HALO) to $75 from $65 and keeps an Equal Weight rating on the shares. The firm sees the company’s near-term outlook
Halozyme Therapeutics Earnings Call Transcript: Q4 2025
Record 2025 results with 38% revenue growth, major portfolio expansion, and strong royalty gains from ENHANZE-enabled products. 2026 guidance projects 22%–30% revenue growth, new clinical programs, and continued strategic acquisitions.
Halozyme reports Q4 EPS 24c vs. $1.26 last year
Reports Q4 revenue $451.8M, consensus $446.14M. “2025 was a pivotal year for Halozyme (HALO) as we delivered record total revenue of $1.4B, which was the result of continued growth in
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions of Elektrofi's Hypercon™ Technolo...